Melik Ulusu - Cytek Biosciences Senior Chain
| CTKB Stock | USD 6.53 0.03 0.46% |
Executive
Melik Ulusu is Senior Chain of Cytek Biosciences
| Address | 47215 Lakeview Boulevard, Fremont, CA, United States, 94538 |
| Phone | 877 922 9835 |
| Web | https://cytekbio.com |
Cytek Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.0274) % which means that it has lost $0.0274 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0254) %, meaning that it created substantial loss on money invested by shareholders. Cytek Biosciences' management efficiency ratios could be used to measure how well Cytek Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of November 29, 2024, Return On Tangible Assets is expected to decline to -0.03. The current year's Return On Capital Employed is expected to grow to -0.06. At present, Cytek Biosciences' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 107.5 M, whereas Total Assets are forecasted to decline to about 389 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Aaron Berutti | Treace Medical Concepts | 45 | |
| Shana Zink | Treace Medical Concepts | N/A | |
| Dan Yarbrough | Orthofix Medical | N/A | |
| Suzanne Armstrong | Orthofix Medical | N/A | |
| Matthew CPA | Apyx Medical | 55 | |
| Manohar Raheja | Sight Sciences | N/A | |
| Grgoire Ramade | Inogen Inc | 54 | |
| Krishna Jhaveri | Inogen Inc | N/A | |
| Teryl Sides | SurModics | 54 | |
| Irene Thomas | Neuropace | 55 | |
| Sarah Huber | Pulmonx Corp | N/A | |
| Vijay Paliwal | Inogen Inc | N/A | |
| Amy Treadwell | Neuropace | N/A | |
| Frank Vizesi | Orthofix Medical | N/A | |
| Tom Huang | Sight Sciences | N/A | |
| Amy Yanta | Electromed | N/A | |
| Kevin Smith | Inogen Inc | 53 | |
| Irina Ridley | Neuropace | 38 | |
| Reay MD | Sight Sciences | N/A | |
| David JD | Pulmonx Corp | 63 | |
| Taylor Erickson | Treace Medical Concepts | N/A | |
Management Performance
| Return On Equity | -0.0254 | ||||
| Return On Asset | -0.0274 |
Cytek Biosciences Leadership Team
Elected by the shareholders, the Cytek Biosciences' board of directors comprises two types of representatives: Cytek Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cytek. The board's role is to monitor Cytek Biosciences' management team and ensure that shareholders' interests are well served. Cytek Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cytek Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Wenbin Jiang, CEO President | ||
| Todd Garland, Chief Officer | ||
| Ming Yan, CTO Director | ||
| Melik Ulusu, Senior Chain | ||
| Mark Edinger, VP Affairs | ||
| Allen Poirson, Senior Development | ||
| Connie Wedel, Chief Officer | ||
| Chris Williams, Chief Officer | ||
| Paul Goodson, Head Relations | ||
| William McCombe, Chief Officer | ||
| Philippe Busque, Senior Services | ||
| Patrik Jeanmonod, Head Analytics | ||
| Valerie JD, General Secretary | ||
| Paul Williams, Chief Officer |
Cytek Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cytek Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0254 | ||||
| Return On Asset | -0.0274 | ||||
| Profit Margin | (0.05) % | ||||
| Operating Margin | (0.08) % | ||||
| Current Valuation | 574.01 M | ||||
| Shares Outstanding | 128.81 M | ||||
| Shares Owned By Insiders | 8.84 % | ||||
| Shares Owned By Institutions | 59.02 % | ||||
| Number Of Shares Shorted | 4.11 M | ||||
| Price To Book | 2.17 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cytek Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cytek Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytek Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytek Biosciences Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytek Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytek Biosciences. If investors know Cytek will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytek Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.658 | Earnings Share (0.08) | Revenue Per Share 1.527 | Quarterly Revenue Growth 0.073 | Return On Assets (0.03) |
The market value of Cytek Biosciences is measured differently than its book value, which is the value of Cytek that is recorded on the company's balance sheet. Investors also form their own opinion of Cytek Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cytek Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytek Biosciences' market value can be influenced by many factors that don't directly affect Cytek Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytek Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytek Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytek Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.